2nd Dec 2016 07:09
LONDON (Alliance News) - Drugmaker GlaxoSmithKline PLC on Friday said its Relvar Ellipta treatment for chronic obstructive pulmonary disease has been approved in Japan.
The inhaler has been approved by the Japanese Ministry of Health, Labour & Welfare for COPD, having been approved for asthma treatment in 2013.
"We are delighted with this approval of Relvar Ellipta, our third COPD treatment to gain marketing authorisation in Japan in under three years, and believe it will be an important new option for appropriate patients with COPD, as well as those with asthma," said Eric Dube, senior vice-president and head of Glaxo's global respiratory franchise.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline